Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results

British Journal of Cancer

Volumn 87, Issue 5, 2002, Pages 562-566

  Burgers, J A ^a   Arance, A ^a,b   Ashcroft, Linda ^a,b   Hodgetts, J ^a,b   Lomax, L ^a,b   Thatcher, N ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Participation; Randomised trial; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT REFUSAL;

EID: 0037183685     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600433     Document Type: Article

References (34)

1. Study demonstrates link between cancer survival and wealth
2. Selection bias in clinical trials
3. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
4. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
5. Inoperable non -small -cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Counsil by its Lung Cancer Working Party
6. Socioeconomic status and cancer survival
7. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients
8. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma
9. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials
10. Ethical issues in the design and conduct of randomised controlled trials
11. Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer
12. Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studies
13. Female patients with small cell lung cancer live longer than male patients
14. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland
15. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - An analysis of 1, 714 consecutive patients
16. Nephroblastoma: Treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial
17. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
18. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase III trial
19. Treatment of small-cell lung cancer on protocol: Potential bias of results
20. Small-cell carcinoma of the lung: Derivation of a prognostic staging system
21. Limited-stage small-cell lung cancer: Patient survival after combined chemotherapy and radiation therapy with and without treatment protocols
22. Socioeconomic variation in cancer survival in the southeastern Netherlands, 1980-1989
23. Trends in cancer survival in England and Wales
24. Volunteers or victims: Patients' views of randomised cancer clinical trials
25. Longevity in small cell lung cancer. A report to the lung cancer subcommittee of the United Kingdom Coordinating Committee for Cancer Research
26. Recruitment of patients with lung cancer into a randomised clinical trial: Experience at two centres
27. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukemia
28. Centralised treatment, entry to trials and survival
29. The value of anatomic staging and other prognostic factors in small cell lung cancer management: A view of European studies
30. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial
31. The addition of cisplatin to cyclophosphamide - Doxorubicin - Etoposide combination chemotherapy in the treatment of patients with small-cell lung cancer carcinoma: A randomized study of 457 patients
32. Childhood NHL in Switzerland: Incidence and survival of 120 study and 42 non-study patients
33. Does clinical experience with a treatment regimen affect survival of lung cancer patients? An analysis based on consecutive randomised trials of the Medical Research Council in small cell and non-small cell tumours
34. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma